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An update on hearing impairment in patients with rheumatoid arthritis
A. Emamifar a,b,*, I.M.J. Hansen b,c
a Department of Medicine, Odense University Hospital, Svendborg Hospital, Svendborg, Denmark
b Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark
c Section of Rheumatology, Department of Medicine, Odense University Hospital, Svendborg Hospital, Svendborg, Denmark
Received 5 September 2017; revised 9 October 2017; accepted 17 October 2017AbstractRheumatoid arthritis (RA) is a systemic, autoimmune disease that present with intra-articular and extra-articular manifestations. Auditory
system may be involved during the course of RA disease due to numbers of pathologies. The link between hearing impairment and RA has been
discussed in the previous literature. In this study we provide an update on the clinical aspect of hearing impairment in RA. We suggest to test
hearing in all newly diagnosed RA patients at diagnosis as well as regularly during the course of disease.
Copyright © 2017, PLA General Hospital Department of Otolaryngology Head and Neck Surgery. Production and hosting by Elsevier
(Singapore) Pte Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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In 2015, we performed a literature review respecting hearing
impairment in patients with rheumatoid arthritis (RA) which is
published in early 2016 (Emamifar et al., 2016a, b, c). In this
supplementary review, we presented data using the published
literature since then. RA is systemic, autoimmune disease with
a prevalence of 1% in the general population (Jensen Hansen
et al., 2017). Although patients with RA basically presentgy Head and Neck Surgery. Production and hosting by Elsevier (Singapore)
eativecommons.org/licenses/by-nc-nd/4.0/).
2 A. Emamifar, I.M.J. Hansen / Journal of Otology 13 (2018) 1e4with articular manifestations, RA may involve other organ
systems, mostly due to inflammatory process, with direct effect
on long term outcome. In this direction, the probability of
auditory system involvement in RA has been one of the areas
with great interest. However, the results of previous studies
evaluating the link between RA and hearing impairment are
really confusing. Therefore we performed a literature review,
using Pubmed database, to provide an update on the clinical
aspect of hearing impairment in RA [Table 1].
Sensorineural hearing loss (SNHL) has been reported as
the most common hearing impairment in RA with a preva-
lence of approximately 12e80% following by conductive
hearing loss (CHL) and mixed hearing loss (MHL)
(Emamifar et al., 2016a; Lobo et al., 2016; Ahmadzadeh
et al., 2017). The pathogenesis of hearing impairment in
RA is not clearly understood, though it may be related to
arthritis of incudostapedial and incudomalleolar joints
[Fig. 1], causing CHL, or due to vasculitis, neuritis or
deposition of immune complex that results in SNHL. Other
etiologies e.g. drug induced (salicylates, non-steroidal anti-
inflammatory drugs, antimalarial and some kinds of disease
modifying antirheumatic drugs), rheumatoid nodules
(causing CHL), etc. have also been reported. Environmental
factors i.e. smoking, alcohol and noise exposure can affect
the auditory system in healthy individuals as well as RA
patients (Emamifar et al., 2016a).
2. Characteristic of hearing impairment
SNHL was the most common hearing impairment, detected
by pure tone audiometry, and affects particularly high fre-
quency, though involvement of middle and low frequencies
have also been reported (Lasso de la Vega et al., 2016;
Yildirim et al., 2016; Jeong et al., 2016). Extended high fre-
quency audiometry, which evaluates very high frequencies
(>8000 Hz), can detect hearing impairment at earlier stages. In
a case control study, Lasso de la Vega et al. found a 33.6 time
higher chance of hearing impairment, detected by extended
high frequency audiometry compared to pure tone audiometry
(Lasso de la Vega et al., 2016). The hearing impairment at
high frequencies may be due to vasculitis/neuritis that affectsTable 1
A summary of published studies evaluating the link between rheumatoid arthritis
Authors RA patients
(n)
Mean of age
(year)
1. Lasso de la Vega et al., 2016 53 50.5
2. Yildirim et al., 2016 88 46.9
3. Jeong et al., 2016 297 56.7
4. Lobo et al., 2016 43 48.9
5. Rahne et al., 2017 22 56.6
6. Ahmadzadeh et al., 2017 42 53.0
NS: non significant results.
a Statistically significant difference in hearing thresholds between RA patients an
by pure tone audiometry or extended high frequency audiometry.
b Hearing impairment was defined according to 2 categories of frequency (low/m
and 2000 Hz, and high frequency, 3000, 4000, and 6000 Hz.the cochlea and cochlear nerve leading to SNHL in RA pa-
tients. On the contrary to the studies revealed a positive cor-
relation between RA and hearing impairment (Lasso de la
Vega et al., 2016; Yildirim et al., 2016; Jeong et al., 2016),
Lobo FS and Rahne T in separate case control studies did not
find statistically significant increase in the incidence of hear-
ing impairment in patients with RA compared to the control
groups (Lobo et al., 2016; Rahne et al., 2017). Besides,
Ahmadzadeh A in a case control study of 42 RA patients
compared to the age- and sex-matched healthy individuals
demonstrated a significantly higher bone conduction threshold
in the patients with RA in low frequencies and in the mean of
500e2000 Hz frequencies. The prevalence of CHL, SNHL
and MHL, however, were not statistically different between
the RA and control groups when definitions of hearing loss
were considered (unaided pure tone threshold level of
25 dB) (Ahmadzadeh et al., 2017).2.1. Otoacoustic emissions (OAEs)Otoacoustic emissions (OAEs), where sounds emitted by
the cochlea either spontaneously or evoked by acoustic stim-
uli, can be employed to determine cochlear status, specifically
hair cell function. Different methods are available. OAEs can
be altered by RA disease, despite of normal hearing in RA
patients that represents an early stage of hearing impairment
(Emamifar et al., 2016a). Lobo FS with the aim of Distortion
product OAEs detected a significant reduced amplitude of
OAEs at 2000 Hz bilaterally compared with control subjects
(Lobo et al., 2016). However Rahne T and Ahmadzadeh A did
not find any decrease in OAE amplitudes evaluated by
Distortion product OAEs (Ahmadzadeh et al., 2017; Rahne
et al., 2017).
3. Demographics and hearing impairment
Aging, gender, current smoking and level of education may
affect prevalence of hearing impairment in RA (Emamifar
et al., 2016a; Lasso de la Vega et al., 2016; Jeong et al.,
2016). Elderly male patients with RA seem to be more
prone to hearing impairment (Lasso de la Vega et al., 2016).and hearing impairment.
Female
gender %
Disease
duration
(months)
Difference in
hearing threshold
(Hz)a
73.6 e 6000 to 18,000 Hz
72.7 58.3 1000 Hz, 2000 Hz, 4000 Hz
75.4 e Low/mid and high frequenciesb
86.6 123.8 6000 Hz
72.7 49.2 NS
92.9 103.2 500 to 2000 Hz
d control groups considering both air conduction and bone conduction detected
id and high) as follows (average values in Hz): low/mid frequency, 500, 1000,
Fig. 1. Possible sites for arthritis in the ear (shown by blue arrows).
3A. Emamifar, I.M.J. Hansen / Journal of Otology 13 (2018) 1e4Nicotine-related vasoconstriction and subsequent decrease in
the oxygen concentration can cause external hair cells damage
and declined cochlear function leading to SNHL in both active
and passive smokers (Emamifar et al., 2016a). Higher level of
education may play a protective role against hearing impair-
ment, since individuals with higher level of education prob-
ably work in a better work place with less noise exposure
(Jeong et al., 2016).
4. RA disease characteristic and hearing impairment
Lobo FS found a relationship between hearing impairment
and longer disease duration (Lobo et al., 2016). This, however,
is not independent of age. A significant association, especially
at high frequencies, between hearing impairment and disease
activity was detected in a study by Yildirim A, where the
audiometric results of 62 patients with active disease was
compared with 26 patients in remission (Yildirim et al., 2016).
Disease Activity Score in 28 JointseC-Reactive Protein
(DAS28-CRP) was measured based on a count of 28 tender
joints, 28 swollen joints, patients global assessment and lab-
oratory result of CRP, which is widely used in clinics (Yildirim
et al., 2016; Jensen Hansen et al., 2017). Rahne T observed a
correlation between the cumulative steroid dose and the air-
bone gap of the right ear, since the cumulative steroid dose
reflects the disease severity, it can be postulated that incu-
dostapedial and incudomalleolar joints might be affected insevere cases (Rahne et al., 2017). However, involvement of
these joints in RA may cause no clinical symptoms, since
these two joints are functionally fixed during sound trans-
mission. In the study by Lobo FS significant correlations be-
tween anti-cyclic citrullinated peptide (anti-CCP) as well as
anti-mutated citrullinated vimentin (anti-MCV) and hearing
impairment were found (Lobo et al., 2016). This is of
importance, because there is evidence that anti-CCP and anti-
MCV are associated with severe extra articular manifestation
(Turesson et al., 2007, 2013). Anti-CCP is frequently used as
one of the criteria to diagnose RA in daily practice, however,
the performance of anti-MCV is generally limited to the
research purposes.
5. Treatment
The goal for the treatment of RA is to achieve sustained
remission (DAS28 < 2.6) or low disease activity
(DAS28  3.2) in every patients (Smolen et al., 2017). If
hearing impairment is concurrently diagnosed in RA patients,
initiation or intensification of disease-modifying antirheumatic
drugs (DMARDs), eventually supplemented with steroid
treatment, should be considered. Steroid is the mainstay of the
medical treatment if patients are on the maximum doses of
DMARDs. Intratympanic application of steroids with opti-
mized dosage may results in better outcome in some instances
(Emamifar et al., 2016a).
4 A. Emamifar, I.M.J. Hansen / Journal of Otology 13 (2018) 1e46. Conclusion
Based on this study and previously published articles, we
think that there is an association between RA and hearing
impairment. However the extents of the involvement as well as
the predisposing factors are not well understood. In addition,
the heterogeneity of the study populations in previous studies
i.e. different male/female ratios, disease duration and disease
severity as well as different treatment strategies resulted in
conflicting results. The authors propose the screening of RA
patients for hearing impairment at diagnosis and thereafter on
a regular basis depending on the clinical symptoms. Extended
high frequency audiometry could be of an advantage for
earlier diagnosis. Once again, the need for a meta-analysis
study in this field, to make a definite conclusion, is clearly felt.
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